Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- JMA Deputy Chief Shigematsu Joins Chuikyo Succeeding Kimori
October 6, 2022
- Chuikyo Kicks Off Debate on FY2023 Off-Year Drug Price Revision
October 6, 2022
- Japan Panel OKs Inclusion of Silgard 9 into National Immunization Program
October 5, 2022
- Japan Convenes Diet Session; Bill Submission Planned to Amend Infectious Disease Act, Medical Care Act
October 4, 2022
- Govt Plans to Designate Key Resources Before End of Year: Minister
October 4, 2022
- MHLW Panel Proposes Lifting Bans on Cannabis-Derived Drugs, Introducing Distribution Control
October 3, 2022
- Japan Ends Supply of AstraZeneca’s COVID Jab, 13.5 Million Doses Discarded
October 3, 2022
- PMDA Will “Appropriately Review” Lecanemab If Filed: Minister
October 3, 2022
- Wholesalers Question Inflexibility in Official Pricing, Sees Limit to Addressing Rising Costs
September 30, 2022
- Crecon President Sounds Alarm over Hollowing-Out of Domestic Manufacturing
September 30, 2022
- Trade Group Calls for New Pricing Model for Regenerative Medicine Products
September 30, 2022
- Japan Set to Distribute Pfizer’s COVID Jab for 6 Months to 4 Years of Age from Late October
September 30, 2022
- 2% Buffer Zone Has Multiple Functions, Should Not Be Reduced: JPWA
September 30, 2022
- Japan Panel to Discuss Comirnaty for Kids Aged 6 Months to 4 Years on Oct. 5
September 29, 2022
- Japan Approves Mounjaro, Tezspire, Fintepla, Label Expansions for Rinvoq/Skyrizi, Keytruda, and More
September 27, 2022
- MHLW’s Healthcare DX Promotion Team Holds 1st Meeting, Sets Up 2 Task Forces
September 27, 2022
- Keytruda Gets Label Update to Add Adjuvant Data for Melanoma
September 27, 2022
- Discussions on FY2023 Drug Price Revision Method to Be Held by Chuikyo: Minister
September 26, 2022
- Cost Rates of Drugs in Japan Worsen on Inflation, Weaker Yen: FPMAJ Survey
September 26, 2022
- Japan, US, European Trade Groups Eye Introduction of “Official Margins” in Price Revision Review
September 26, 2022
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…